Insider Trading Alert - LCI, POWI And LGND Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 20, 2014, 164 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $87.78 to $643,360,199,551.68.

Highlighted Stocks Traded by Insiders:

Lannett Company (LCI) - FREE Research Report

Drabik David A who is Director at Lannett Company sold 10,000 shares at $44.54 on Feb. 20, 2014. Following this transaction, the Director owned 23,750 shares meaning that the stake was reduced by 29.63% with the 10,000-share transaction.

The shares most recently traded at $44.64, up $0.10, or 0.22% since the insider transaction. Historical insider transactions for Lannett Company go as follows:

  • 4-Week # shares bought: 500
  • 12-Week # shares bought: 8,600
  • 24-Week # shares bought: 8,600

The average volume for Lannett Company has been 390,700 shares per day over the past 30 days. Lannett Company has a market cap of $1.6 billion and is part of the health care sector and drugs industry. Shares are up 37.34% year-to-date as of the close of trading on Thursday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 78.5. Currently there are 5 analysts that rate Lannett Company a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings rates Lannett Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Lannett Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers